JP2023515573A5 - - Google Patents
Info
- Publication number
- JP2023515573A5 JP2023515573A5 JP2022551284A JP2022551284A JP2023515573A5 JP 2023515573 A5 JP2023515573 A5 JP 2023515573A5 JP 2022551284 A JP2022551284 A JP 2022551284A JP 2022551284 A JP2022551284 A JP 2022551284A JP 2023515573 A5 JP2023515573 A5 JP 2023515573A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- antigen
- activatable
- shielded
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981782P | 2020-02-26 | 2020-02-26 | |
| US62/981,782 | 2020-02-26 | ||
| PCT/US2021/019331 WO2021173612A1 (en) | 2020-02-26 | 2021-02-24 | Activatable antigen binding proteins with universal masking moieties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515573A JP2023515573A (ja) | 2023-04-13 |
| JP2023515573A5 true JP2023515573A5 (enExample) | 2024-03-06 |
Family
ID=75108796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551284A Pending JP2023515573A (ja) | 2020-02-26 | 2021-02-24 | 普遍的な遮蔽性部分を有する活性化可能な抗原結合性タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230183377A1 (enExample) |
| EP (1) | EP4110817A1 (enExample) |
| JP (1) | JP2023515573A (enExample) |
| CN (1) | CN115485300A (enExample) |
| CA (1) | CA3168986A1 (enExample) |
| WO (1) | WO2021173612A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| JPWO2024071043A1 (enExample) * | 2022-09-30 | 2024-04-04 | ||
| WO2025040567A1 (en) * | 2023-08-18 | 2025-02-27 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
| CN119234000B (zh) * | 2023-09-25 | 2026-04-17 | 深圳湾实验室 | 可激活穿膜构建体和降解子 |
| WO2025125118A1 (en) * | 2023-12-11 | 2025-06-19 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
| WO2025240659A2 (en) * | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| CN119776391A (zh) * | 2024-12-23 | 2025-04-08 | 四川康德赛医疗科技有限公司 | 编码抗体-抗原融合蛋白的mRNA或mRNA-LNP复合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251202A (en) | 1881-12-20 | Farm-gate | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| AR076508A1 (es) | 2009-05-01 | 2011-06-15 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| WO2016019144A2 (en) | 2014-07-30 | 2016-02-04 | Sangamo Biosciences, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US9949700B2 (en) | 2015-07-22 | 2018-04-24 | Inneroptic Technology, Inc. | Medical device approaches |
| MX2019003674A (es) | 2016-09-30 | 2021-01-08 | Univ California | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. |
| US11939385B2 (en) * | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| SG11202004864TA (en) * | 2017-12-01 | 2020-06-29 | Seattle Genetics Inc | Cd47 antibodies and uses thereof for treating cancer |
| US20210115106A1 (en) * | 2017-12-07 | 2021-04-22 | Janux Therapeutics, Inc. | Modified t cell receptors |
-
2021
- 2021-02-24 CA CA3168986A patent/CA3168986A1/en active Pending
- 2021-02-24 CN CN202180030293.6A patent/CN115485300A/zh active Pending
- 2021-02-24 JP JP2022551284A patent/JP2023515573A/ja active Pending
- 2021-02-24 EP EP21713200.0A patent/EP4110817A1/en not_active Withdrawn
- 2021-02-24 US US17/802,433 patent/US20230183377A1/en not_active Abandoned
- 2021-02-24 WO PCT/US2021/019331 patent/WO2021173612A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515573A5 (enExample) | ||
| JP7638531B2 (ja) | Ｈｅｒ３に対する抗原結合タンパク質 | |
| AU2018304711A1 (en) | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof | |
| CN114591433A (zh) | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 | |
| CN104271602A (zh) | 双特异性抗体 | |
| CA2471206A1 (en) | Individualized anti-cancer antibodies | |
| US12391770B2 (en) | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | |
| CN113646328A (zh) | 一种免疫细胞因子及其制备与用途 | |
| TW202200619A (zh) | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 | |
| CN113943371B (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| CN119233993A (zh) | 用于靶向t细胞活化的cd28双特异性抗体 | |
| CA3052291A1 (en) | Anti-kir3dl1 antibodies | |
| CN118946587A (zh) | 抗pd-1单克隆抗体及其衍生物和用途 | |
| EP4683654A1 (en) | Sirp variants and uses thereof | |
| JP2025513930A5 (enExample) | ||
| CN119013298A (zh) | 抗cd39纳米抗体及其应用 | |
| JP2023533857A (ja) | 抗ｋｌｋ２抗体に対する抗イディオタイプ抗体 | |
| US20220175945A1 (en) | Antibodies and enonomers | |
| CN118974100A (zh) | 针对人tim-3和人cd39的双特异性抗体和其用途 | |
| Xu et al. | Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy | |
| US20170088604A1 (en) | Preparation and selection of cells for producing bispecific antibodies | |
| US20230287082A1 (en) | Nkp30 binders | |
| Claus et al. | Article Not peer-reviewed version | |
| HK40129137A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| CN117615782A (zh) | 包含结合至共价肽偶联物的抗体的组合物和方法 |